Welcome to our dedicated page for Celanese Del SEC filings (Ticker: CE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Celanese Corporation filings document the regulatory disclosures of a global chemical and specialty materials company. Its Form 8-K reports cover operating results, earnings releases, Regulation FD investor materials, non-GAAP reconciliations, dividend-related corporate actions, and material governance events.
Celanese proxy and annual-meeting filings describe director elections, shareholder voting matters, auditor ratification, executive compensation votes, board composition, and compensation practices. The filing record also includes capital-structure references for common stock and senior unsecured note classes, tying formal disclosures to the company’s financing, governance, and public-company reporting obligations.
Celanese Corp. ownership disclosure: Capital Research Global Investors filed an amendment reporting beneficial ownership of 4,696,916 shares of Celanese common stock, equal to 4.2% (as of 03/31/2026) of the 111,922,758 shares the filer believes are outstanding. The filing attributes sole voting and sole dispositive power over all reported shares to the filer.
Chinn Bruce E. reported acquisition or exercise transactions in this Form 4 filing.
Celanese Corp director Bruce E. Chinn received an annual equity grant of 2,975 shares of common stock in the form of restricted stock units. These units were awarded at no cash cost to him under the Company's Amended and Restated 2018 Global Incentive Plan and vest in full on the one-year anniversary of the grant date.
After this compensation-related grant, Chinn directly holds 7,261 shares of Celanese common stock. This filing reflects routine director equity compensation rather than an open-market purchase or sale.
Celanese Corp director Anne P. Noonan reported receiving a grant of 2,975 shares of common stock as a compensation award. The Form 4 shows this as a grant or award acquisition at a price of $0.00 per share, bringing her directly held position to 2,975 shares.
A footnote explains this is an annual grant of restricted stock units under Celanese’s Amended and Restated 2018 Global Incentive Plan, which vest in full on the one-year anniversary of the grant date.
Celanese Corp director Michael Koenig reported routine equity compensation activity. On May 11, 2026, he acquired 2,975 shares of Common Stock as a grant/award of restricted stock units with no cash paid per share. According to the footnotes, these units were granted under the Company’s Amended and Restated 2018 Global Incentive Plan and will vest in full on the one-year anniversary of the grant date.
On May 9, 2026, 1,013 shares of Common Stock were disposed of at $57.51 per share to cover taxes due upon vesting and settlement of performance-based restricted stock units, a non-market tax-withholding transaction. After these transactions, Koenig directly holds 8,320 shares of Celanese common stock.
MOORTHY GANESH reported acquisition or exercise transactions in this Form 4 filing.
Celanese Corp director Ganesh Moorthy reported an annual equity compensation grant in the form of restricted stock units. He received 2,975 shares of Common Stock as a grant or award at a stated price of $0.00 per share under the company’s Amended and Restated 2018 Global Incentive Plan. These restricted stock units vest in full on the one-year anniversary of the grant date, meaning the shares become fully owned after that period. Following this award, Moorthy directly holds 8,990 shares of Celanese common stock and indirectly holds 3,000 shares through the Ganesh and Hema Moorthy Revocable Living Trust. This filing reflects routine director compensation rather than an open-market purchase or sale.
Celanese Corp director Deborah J. Kissire reported compensation-related equity movements. On May 9, 2026, 3,376 Restricted Stock Units vested, and she deferred the resulting 3,376 shares of Common Stock into 3,376 shares of phantom stock under the company’s 2008 Deferred Compensation Plan, leaving 1,100 Common shares directly held.
On May 11, 2026, she received an annual grant of 2,975 restricted stock units under the Amended and Restated 2018 Global Incentive Plan, which vest in full one year after grant. She also received 2.984 additional phantom stock shares as dividend equivalents, bringing her phantom stock balance to 9,303.777 units, each representing the right to receive one share of Common Stock.
Celanese Corp director Kim K.W. Rucker reported routine equity compensation and deferral activity. On May 9, 2026, 3,376 Restricted Stock Units vested and were exchanged for 3,376 shares of phantom stock under the company’s 2008 Deferred Compensation Plan, in place of receiving common shares.
On the same date, the director’s common stock position decreased by 3,376 shares to reflect this deferral, while the phantom stock balance increased by the same amount. On May 11, 2026, the director received an annual grant of 2,975 restricted stock units in common stock and an additional 4.796 shares of phantom stock as dividend equivalents.
After these transactions, the director directly holds 3,031 shares of Celanese common stock and 12,900.519 shares of phantom stock, each phantom share representing the right to receive one share of common stock in the future. These are compensation and deferral arrangements rather than open-market stock purchases or sales.
Celanese Corp director Kathryn Hill received new equity-based compensation on May 11, 2026. She was granted 2,975 shares of Common Stock in the form of restricted stock units under the company’s Amended and Restated 2018 Global Incentive Plan, which vest in full one year after the grant date. Following this award, she directly holds 19,783.48 shares of Common Stock.
Hill also acquired 0.575 shares of phantom stock as dividend equivalents on compensation deferred under the company’s 2008 Deferred Compensation Plan. Each phantom share represents the right to receive one share of Common Stock, bringing her phantom stock balance to 1,141.769 units. These are compensation-related grants, not open‑market purchases.
Celanese Corp director Christopher J. Kuehn reported equity compensation and a deferral election, not open-market trading. On May 11, he received 2,975 shares of Common Stock as a grant with a reported price of $0.00 per share, leaving him with 2,975 Common shares directly owned.
On May 9, 3,376 Restricted Stock Units vested, and instead of taking delivery of 3,376 Common shares, he exchanged them for 3,376 shares of phantom stock under Celanese’s 2008 Deferred Compensation Plan. Each phantom stock share represents the right to receive one Common share, payable in stock at a later date or upon his termination as a director.
Celanese Corp director Edward G. Galante received new equity-based compensation. On May 11, 2026, he was granted 4,676 shares of Common Stock in the form of restricted stock units under the Amended and Restated 2018 Global Incentive Plan. These units vest in full on the one-year anniversary of the grant date.
He also acquired 3.429 shares of phantom stock as dividend equivalents on deferred compensation under the 2008 Deferred Compensation Plan. Each phantom stock unit represents the right to receive one share of Common Stock and becomes payable in shares after his service as a director ends. Following these awards, he directly holds 26,053 shares of Common Stock and 6,810.222 phantom stock units.